Literature DB >> 31074940

Reply.

Alfred H J Kim1, Vibeke Strand2, John P Atkinson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31074940      PMCID： PMC6716999          DOI： 10.1002/art.40923

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  10 in total

Review 1.  Systemic lupus erythematosus.

Authors:  Anisur Rahman; David A Isenberg
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

2.  Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.

Authors:  Amy H Kao; Jeannine S Navratil; Margie J Ruffing; Chau-Ching Liu; Douglas Hawkins; Kathleen M McKinnon; Natalya Danchenko; Joseph M Ahearn; Susan Manzi
Journal:  Arthritis Rheum       Date:  2010-03

3.  Association of Autoantibody Quantification With Systemic Lupus Erythematosus Disease Activity: Comment on the Article by Kim et al.

Authors:  Xiaojun Tang; Mingzhe Ning; Yantong Zhu; Yun Zhu; Yang Xu; Si Wu; Xuebing Feng
Journal:  Arthritis Rheumatol       Date:  2019-07-19       Impact factor: 10.995

4.  Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.

Authors:  David S Pisetsky; Diane M Spencer; Peter E Lipsky; Brad H Rovin
Journal:  Ann Rheum Dis       Date:  2018-02-09       Impact factor: 19.103

5.  Intracellular C3 Protects Human Airway Epithelial Cells from Stress-associated Cell Death.

Authors:  Hrishikesh S Kulkarni; Michelle L Elvington; Yi-Chieh Perng; M Kathryn Liszewski; Derek E Byers; Christopher Farkouh; Roger D Yusen; Deborah J Lenschow; Steven L Brody; John P Atkinson
Journal:  Am J Respir Cell Mol Biol       Date:  2019-02       Impact factor: 6.914

6.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

7.  Complement (C3) metabolism in systemic lupus erythematosus in relation to the disease course.

Authors:  A J Swaak; A van Rooyen; C Vogelaar; M Pillay; E Hack
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

Review 8.  Anti-DNA antibodies--quintessential biomarkers of SLE.

Authors:  David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2015-11-19       Impact factor: 20.543

9.  Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.

Authors:  Jill Buyon; Richard Furie; Chaim Putterman; Rosalind Ramsey-Goldman; Kenneth Kalunian; Derren Barken; John Conklin; Thierry Dervieux
Journal:  Lupus Sci Med       Date:  2016-09-30

10.  Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.

Authors:  Alfred H J Kim; Vibeke Strand; Deepali P Sen; Qiang Fu; Nancy L Mathis; Martin J Schmidt; Robin R Bruchas; Nick R Staten; Paul K Olson; Chad M Stiening; John P Atkinson
Journal:  Arthritis Rheumatol       Date:  2019-01-24       Impact factor: 10.995
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.